Natural Peptides – Your real way to health & rejuvenation

Proteins and peptides carry out important biological functions and are fundamental building blocks of cells. Structurally, proteins and peptides are very similar, being made up of chains of amino acids that are held together by peptide bonds (also called amide bonds). So, what distinguishes a peptide from a protein?

Proteins & Peptides are created by the polymerization of amino acids, a process in which amino acids are joined together in chains. Shorter strings of amino acids may be referred to as peptides, while chains with more than 50 amino acids bonded and with specific 3D structures are considered proteins.

Our peptides are multi-component peptide complexes of the next-generation used for prevention, rehabilitation and rejuvenation. These peptides are a 3+1 formula, containing 3 main groups of nutrients in 1 vegetarian capsule. Therapeutic properties of natural peptides of animal origin and their effect in the small intestine are preserved in a vegetable capsule only.

The combination of balanced ingredients and a vegetarian capsule makes each of our peptides, undoubtedly, “golden” by the number of useful properties and efficacy.

We sell peptides for hormonal regulations, anti-aging, prevention and maintenance, fitness and sport performance boost, specific for men’s and respectively women’s health, for skin health and cosmetological applications.

Learn more about the extraordinary benefits for your health, anti-aging, fitness, hormonal regulation by watching the following video:

Color Tuning 64 – The Success Key to Body Balance & Rejuvenation

Today we all know the health benefits of bioresonance, psychosomatic, radionics, light & sound therapy, homeopathy, holistic medicine. There are hundreds of devices out there for one or another modality and treatment; how many systems do you know which bundle synergistically all these modalities to heal and rejuvenate your body?

In a previous presentation, we learned about Tao Medical, an amazing and unique combination between Chinese acupuncture, psychosomatic medicine, biofeedback and radionics. (see here).

Today we take you on another holistic medicine pathway, where a symphony of colors, light, sound, radionics, psychosomatic, homeopathy offers a diagnostic and therapy alternative to Tao Medical. Color Tuning 64 is used for holistic diagnostic and multiple radiant auto-regulation therapy. Color Tuning 64 harmonizes the bioenergetic & informational vibrations of body zones; human body is divided per Kabbalah Life Tree in in 64 body zones.

Diagnostic and Therapy are automatically elaborated and applied on psychosomatic, bioenergetic and epigenetic levels. The system works in remote, has encoders for magnetic cards and homeopathic remedies, transmission of therapy can be done using radionic scalar waves as well as direct transmissions using the hand electrodes, Color Tuning 64 QRS comes with unique features such as:

  • Hardware: bioenergetic tuner with physiological multi-sensor connection such as brass electrodes to measure skin galvanic response, or light active hand pads to measure skin response after light provocation.
  • Audio-visual biofeedback for stress balance
  • Dynamic 3D Scans on all 64 body zones with display of unbalanced zones
  • Auto-regulation on selected body zones showing highest out of balance body zones
  • Psychosomatic scan and therapy based on Dr. Drew technique
  • Therapy with color-tone cascades. Color classification by indication (psycho-energetic resonance) as well as freely programmable color sequences
  • Optimal system regulation by combination of information medicine (radionics) and bioenergetic effect of the color light systems (390-630 nm)
  • Unlimited number of patients are listed
  • Color Tuning 64 comes with a software to be installed on a computer controlling the hardware

Color Tuning 64 has unlimited medical therapy indications, such as: Psychosomatic disorders, emotional stress, exhaustion, burn out syndrome, systemic functional disorders, dermatological problems, immunological weakness, neurological disorders, pain relief with analgesic effect, wound & burns fast healing, depressions and SAD therapy, circadian rhythm and jet lag sleep disorders and much more.

Women treated for precursor of breast cancer can expect to live as long as other women

Women over 50 who have been treated for ductal carcinoma in situ (DCIS) are more likely to be alive ten years later than women in the general population, according to new research presented at the European Cancer Congress 2017.

DCIS differs from breast cancer because it is non-invasive, meaning it cannot spread around the body. However, because it can progress into an invasive breast cancer, which can be life-threatening, it is usually treated with surgery, or surgery and radiation therapy. The number of women being diagnosed with DCIS is increasing because it is picked up by breast screening programmes.

The findings, presented at the Congress by Dr Lotte Elshof, showed that, although women with DCIS have a higher risk of dying from breast cancer, overall they have a slightly lower risk of dying from any cause.

Researchers from the Netherlands Cancer Institute say their results should provide reassurance to women who are diagnosed with the disease.

Led by Dr Jelle Wesseling, a breast pathologist at the Netherlands Cancer Institute, the team studied data on almost 10,000 Dutch women who were diagnosed with DCIS between 1989 and 2004. They tracked the patients over an average of 10 years and compared their death rates with the expected mortality in the general population. They found that women over 50 who had been treated for the condition had a ten per cent lower risk of dying from any cause compared to the general population.

Dr Lotte Elshof, research physician and epidemiologist at the Netherlands Cancer Institute who analysed the data, told the Congress: “Being diagnosed with DCIS can be extremely distressing, and research indicates that many women overestimate the risks involved and are confused about treatment. This study should provide reassurance that a diagnosis of DCIS does not raise the risk of dying.

“It might seem surprising that this group of women actually has a lower mortality rate than the general population. However, the vast majority would have been diagnosed via breast screening, which suggests they may be health-conscious and well enough to participate in screening.”

The study shows that DCIS patients had a two and half per cent risk of dying of breast cancer after ten years. At 15 years, the risk was four per cent. These rates are higher than in the general population. However, the study also showed that the rates were getting lower in women diagnosed with DCIS more recently.

Patients were ten per cent less likely to die from all causes combined compared to the general population. Specifically, they had a lower risk of dying from diseases of the circulatory, respiratory and digestive systems and other cancers. The researchers say this finding is important because treating DCIS with radiotherapy could cause side-effects, including damage to nearby organs such as the heart.

The team are beginning an international collaboration with researchers in the UK and USA. This will allow them to increase the size of the study and to try to understand why some cases of DCIS progress into invasive cancer, while others do not.

Professor Philip Poortmans, President-elect of ECCO and head of the Radiation Oncology Department at Radboud university medical center (Nijmegen, The Netherlands), said: “Ductal carcinoma in situ can be a worrying and confusing diagnosis for many women, especially due to the word ‘carcinoma’. Although it should be considered as being clearly different from breast cancer, it can progress into breast cancer, even after removal of the entire breast or after breast conserving therapy consisting of surgery, generally combined with radiation therapy.

“Moreover, those treatments can have side-effects, including on the heart. This research provides reassurance for women diagnosed with DCIS because it shows that they are as likely to be alive ten years after the diagnosis as people in the general population who did not have DCIS. This is also reassuring with regards to the potential risks of side-effects.

“However, we have to recognise that in one fifth of the patients who die, the cause is breast cancer, which is likely to result from progression of the DCIS they were diagnosed with. Therefore, we are eagerly waiting for the results of further research to identify the factors – including age, as clearly shown in this study – that contribute to the risk for recurrence and progression from DCIS for each individual patient.

“Remarkably, the increased risk of dying from breast cancer is completely offset by a lower risk of dying from other causes compared to women in the general population. This might be explained by the generally better health and socioeconomic status of women who regularly participate in breast cancer screening. This could also be tested in the on-going research.”

Provided by: ECCO-the European CanCer Organisation